The Effect of Adding Dexmedetomidine to Ropivacaine for Transversus Abdominis Plane (TAP) Block under Ultrasound-guided for Postoperative Pain Management After abdominal surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004930

Enrollment

Unknown

Registered

2014-07-09

Start date

2014-07-25

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

Group 1:Transversus abdominis plane block with 0.9% saline

Group 2:Transversus abdominis plane block with ropivacaine

Group 3:Transversus abdominis plane block with dexmedetomi

Group 4:Transversus abdominis plane block with dexmedetomidine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Adults who have open abdominal surgery

Exclusion criteria

Exclusion criteria: Age less than 18; body mass index (BMI) more than 40 kg/m2; weight less than 50kg; coagulopathy; a history of relevant drug allergy; chronic hepatic or renal insufficiency; precnancy or breastfeeding; a history of alcohol or analgesics dependence; chronic pain.

Design outcomes

Primary

Measure	Time frame
the time for TAP block;noninvasive blood pressure (NIBP) and heart rate;the concentrations of ropivacaine and dexmedetomid;duration of PACU;Median VAS pain scores while coughing and at rest;QoR40;tramadol requirements;nausea and vomiting during the first 48 postoperat;the time to return to die;	—

Countries

China

Contacts

Public ContactWenzhi Li

wenzhili9@126.com+86 18045159998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026